Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.58 |
| ▸ | JAK1 | P23458 | 15/20 | 0.58 |
| ▸ | JAK3 | P52333 | 6/20 | 0.58 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | ULK1 | O75385 | 1/20 | 0.54 |
| ▸ | PRKCB | P05771 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | PRKCA | P17252 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 1/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102492 | 0.93 | JAK2 (0.63) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL102491 | 0.93 | JAK2 (0.63) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL4092513 | 0.90 | JAK2 (0.61) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL4092510 | 0.90 | JAK2 (0.61) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL29541055 | 0.85 | JAK2 (0.73) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL2144969 | 0.85 | JAK2 (0.73) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL870764 | 0.85 | JAK2 (0.70) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL99130 | 0.84 | JAK2 (0.72) | JAK2JAK1JAK3CITGAK | |
| Trifluoroacetic Acid SCHEMBL29540655 | 0.84 | JAK2 (0.72) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL100839 | 0.83 | JAK2 (0.67) | JAK2JAK1JAK3CITGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.